Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Hepatitis C: Update Bulletin [April 2015]

Product Code:
Release Date:
April 2015

Gain new KOL insights on the latest events happening in Hepatitis C.  Topics covered: Updated warnings and precautions on the Harvoni label, advantages with the combination of daclatasvir and sofosbuvir, TURQUOISE-I study, combination of grazoprevir and elbasvir uses, Phase II PROXY trial, ITHACA and SPARTA clinical development programmes, ALLY data, combination of Viekirax and Exviera and Merck & Co.’s Victrelis.

Key Questions Answered in this Update Bulletin:

  • How important is a shorter (i.e. 4-6 week) treatment regimen for new HCV regimens?
  • How will the updated warnings and precautions on the label for Gilead’s Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) in the US affect its use, and will it spread to other HCV therapies and other markets?
  • What are the specific advantages of a free combination of Bristol-Myers Squibb’s daclatasvir and sofosbuvir offer over Harvoni, and in what situations would it be favoured?
  • What impact will recent National Institute for Health and Care Excellence (NICE) in the UK, which has recommended the reimbursement of Harvoni as a treatment for genotype 1 or 4 chronic hepatitis C, have on its usage in the UK and in Europe?
  • To what extent will the NICE guidance on Sovaldi and Janssen’s Olysio (simeprevir) influence the way in which the combination is used in the UK and the rest of Europe?
  • What could be the potential impact of new data from AbbVie’s TURQUOISE-I study on the treatment of co-infected HCV/HIV patients?
  • How will the combination of Merck & Co.’s grazoprevir and elbasvir be used in the treatment of HCV?
  • To what extent does the data from the Phase II PROXY trial show that Achillion’s ACH-3102 will become the best in class NS5A inhibitor, and how do KOLs perceive the ITHACA and SPARTA clinical development programmes for Achillion’s other pipeline HCV programmes?
  • To what extent is Harvoni routinely used in HCV/HIV co-infected patients and what impact will the ION study data have on its use going forward?
  • How do KOLs view data from Bristol-Myers Squibb’s ALLY study and what, if any, are the advantages of daclatasvir and sofosbuvir compared to the other regimens for HCV/HIV co-infection?
  • What are the potential advantages and disadvantages of AbbVie’s Viekirax, Exviera as a treatment for HCV/HIV co-infected patients?
  • How do US KOLs view the discontinuation of Merck & Co.’s Victrelis (boceprevir)?

When you purchase the full report, you get access to this Update Bulletin.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved